Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + Toripalimab vs Toripalimab as adjuvant therapy in HER2-expressing locally advanced upper tract urothelial carcinoma
ChiCTR2500115471Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in upper tract urothelial carcinoma (UTUC) comparing Toripalimab + Disitamab vedotin with Toripalimab monotherapy (2 arms). Primary endpoint: 2-year disease-free survival rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2500115471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115471.